The Vanguard Group 13D and 13G filings for Supernus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 5:15 pm Purchase | 2023-12-29 | 13G | Supernus Pharmaceuticals, Inc. SUPN | The Vanguard Group | 6,214,731 11.380% | 424,771 (+7.34%) | Filing |
| 2023-02-09 11:32 am Purchase | 2022-12-30 | 13G | Supernus Pharmaceuticals, Inc. SUPN | The Vanguard Group | 5,789,960 10.710% | 276,811 (+5.02%) | Filing |
| 2022-02-10 08:37 am Purchase | 2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | The Vanguard Group | 5,513,149 10.370% | 215,071 (+4.06%) | Filing |
| 2021-02-10 11:57 am Sale | 2020-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | The Vanguard Group | 5,298,078 10.060% | -7,811 (-0.15%) | Filing |